Review article: Current practice and future perspectives in detection and diagnosis of pancreatic cancer

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 10, 1998, Pages 937-948

  Haycox, A ^a,b   Lombard, M ^a   Neoptolemos, J ^a   Walley, T ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Prescribing Research Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC IMAGING; GENE MUTATION; HUMAN; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW;

BIOLOGICAL MARKERS; FORECASTING; HUMANS; MAGNETIC RESONANCE IMAGING; MUTATION; NEOPLASM STAGING; PANCREATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0031718052     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00393.x     Document Type: Review

References (152)

1. Boyle P, Hsieh CC, Maisonneuve P, et al. Epidemiology of pancreatic cancer (1988). Int J Pancreatol 1989; 5(4): 327-46.
2. Bramhall SK, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease in the West Midlands: an epidemiological study. Br J Surg 1995; 82(1): 111-15.
3. Institute National Cancer. Annual Cancer Statistics Review. Dept of Health and Human Services, Bethesda, MD, 1991, (NIH Pub. 91-2789).
4. Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer 1987; 9: 2284-303.
5. Lynch HT, Fusaro LV, Lynch J, Smyrk T. Hereditary pancreatic cancer. Pedigree analysis of pancreatic cancer families. Int J Pancreatol 1994; 16(2-3): 210-14.
6. Sibert J. Hereditary pancreatitis in England and Wales. J Med Genet 1978; 15: 189-201.
7. Lowenfels AB, Maisoneeuve P, Di Magno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst 1997; 89(6): 442-6.
8. Whitcomh DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis in caused by a mutation in the cationic trypsinogen gene. Nature Genet 1996; 14: 141-5.
9. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. New Engl J Med 1993; 328(20): 1433-7.
10. Ekbom A, McLaughlin JK, Karlsson BM, et al. Pancreatitis and pancreatic cancer: a population-based study. J Natl Cancer Inst 1994; 86(8): 625-7.
11. Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 1995; 109: 247-51.
12. Levy P, Menzelxhiu A, Paillot B, Bretagne JF, Flejou JF, Bernades P. Abdominal radiotherapy is a cause for chronic pancreatitis. Gastroenterology 1993; 105(3): 905-9.
13. Cuzick J, Babiker AG. Pancreatic cancer, alcohol, diabetes mellitus and gall bladder disease. Int J Cancer 1989; 43: 415-21.
14. Haddock G, Carter DC. Aetiology of pancreatic cancer. Br J Surg 1990; 77: 1159-66.
15. Gullo L, Pezzilli R, Morsellilabate AM, et al. Diabetes and the risk of pancreatic cancer. Italian Pancreatic Cancer Study Group. New Engl J Med 1994; 331(2): 81-4.
16. Permert J, Larsson J, Westermark GT. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 1994; 330(5): 313-18.
17. Evans JD, Bramhall SR, Neoptolemos JP. Molecular mechanisms in pancreatic disease. In: Treda M, Carter D, eds. Surgery of the Pancreas. In press.
18. Farrow DL, Davis S. Risk of pancreatic cancer in relation to medical history and the use of tobacco, alcohol and coffee. Int J Cancer 1990: 45: 816-20.
19. Ghadirian P, Simard A, Baillargeon J. Tobacco, alcohol and coffee and cancer of the pancreas. Cancer 1991; 67(10): 2664-70.
20. Neoptolemos JP, Ching CH, Rhodes JM, Lemoine N. Cancer of the pancreas and ampulla of Vater. In: Fielding JWL, Allum WH, eds. Pre-malignancy and Early Cancer in General Surgery. Oxford: Oxford University Press, 1996: 66-100.
21. Ghadirian P, Thouez JP, PetitClerc C. International comparisons of nutrition and mortality from pancreatic cancer. Cancer Detection Prevention 1991; 15(5): 357-63.
22. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975; 15: 617-31.
23. Lea AJ. Neoplasms and environmental factors. Ann Royal Coll Surg Engl 1967; 41: 432-8.
24. Garabrant DH, Held J, Langholz B. DDT and pancreas cancer in a case controlled study of chemical workers. J Natl Cancer Inst 1992; 84: 764-71.
25. Greenberg HL, Ott MG, Shore RE. Men assigned to ethylene oxide production or other ethylene oxide related chemical manufacturing: a mortality study. Br J Ind Med 1990; 47(4): 221-50.
26. Benson LO, Teta MJ. Mortality due to pancreatic and lymphopoietic cancers in chlorohydrin production workers. Br J Ind Med 1993; 50: 710-16.
27. Lin RS, Kessler I. A multi-factorial model for pancreatic cancer in man. J Am Med Assoc 1981; 245: 147-52.
28. Hearne FT, Pifer JW, Grose F. Absence of adverse mortality effects in workers exposed to methylene chloride: an update. J Occup Med 1990; 32(3): 234-40.
29. Fontham E. Epidemiology of cancer of the pancreas. In: Howard J, Jordon G, Reber H, eds. Surgical Diseases of the Pancreas, 2nd edn. Philadelphia: Lea & Febiger, 1987.
30. Bakkevold KE, Arnesjo B, Kambestad B. Carcinoma of the pancreas and papular of Vater: presenting symptoms, signs and diagnosis related to stage and tumour site. A prospective multicentre trial in 472 patients. Scand J Gastroenterol 1992; 27: 317-25.
31. Kaiser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903.
32. Nagai H, Kuroda A, Morioka Y. Lymphatic and local spread of T1 and T2 pancreatic cancer. Ann Surg 1986; 204(1): 65-71.
33. Beahrs OH, Myers MH. Manual for Staging of Cancer. Philadelphia: J. B. Lippincott, 1988.
34. Hermreck AS, Thomas CY, Friesen SR. Importance of pathological staging in the surgical management of carcinoma of the exocrine pancreas. Am J Surg 1974; 127: 653-8.
35. UICC. TNM Classification of Malignant Tumours, 4th edn. Berlin: Springer-Verlag, 1987.
36. Society JP. General Rules for Surgical and Pathological Studies on Cancer of the Pancreas. Tokyo: Kanehara Publishing, 1986.
37. Zerbi A, Balzano G, Bottura R, Di Carlo V. Reliability of pancreatic cancer staging classifications. Int J Pancreatol 1994; 15(1): 13-18.
38. Satake K, Nishiwaki H, Yokomatsu H, et al. Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas. Surg Gynecol Obstet 1992; 175: 259-65.
39. Maier W. Magnetic resonance imaging and computed tomography in chronic pancreatitis. In: Beger H, Buschler M, Ditchuneit H, Maltfertheiner P, eds. Chronic Pancreatitis. Berlin: Springer-Verlag, 1996.
40. Balthazar EJ, Chako AC. Computed tomography of pancreatic masses. Am J Gastroenterol 1990; 85: 343-9.
41. Steiner E, Stark DD, Hahn PF, et al. Imaging of pancreatic neoplasms: comparison of MR and CT. Am J Roentgerol 1989; 152(3): 487-91.
42. Palazzo L, Roseau G, Gayet B, et al. Endoscopic ultrasonography in the diagnosis and staging of pancreatic adenocarcinoma: results of a prospective study with comparison to ultrasonography and CT scan. Endoscopy 1993; 25: 143-50.
43. Fujita N. Role of CT in evaluation of the extension of pancreatic cancer. Nippon Igaku Hoshasen Gakkai Zasshi 1990; 25: 1-10.
44. Freeny PC. Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma. Radiol Clin North Am 1989; 27: 121-8.
45. Graham RA, Bankoff M, Hediger R, Shaker HZ, Reinhold RB. Fine needle aspiration biopsy of pancreatic ductal adenocarcinoma: loss of diagnostic accuracy with small tumours. J Surg Oncol 1994; 55(2): 92-4.
46. Sawada Y, Gonda H, Hayashida Y. Combined use of brushing cytology and endoscopic retrograde pancreatography for the early detection of pancreatic cancer. Acta Cytol 1989; 33(6): 870-87.
47. Sangalli G, Livraghi T, Giordano F. Fine needle biopsy of hepatocellular carcinoma: improvement in diagnosis by microhistology. Gastroenterology 1989; 96(2): 524-6.
48. Strachura J, Tomaszewska R, Pietron M, Kulig J. Does microhistology improve the cytological diagnosis of liver and pancreatic tumours? Cytopathology 1991; 2: 39-42.
49. Griffanti-Bartoli F, Arnone GB, Ceppa P, Ravera G, Carrabetta S, Civalleri D. Malignant tumours in the head of the pancreas and the periampullary region. Diagnostic and prognostic aspects. Anticancer Res 1994; 14(2B): 757-66.
50. Ariyama J, Suyama M, Awaga K, et al. The detection and prognosis of small pancreatic carcinoma. Int J Pancreatol 1990; 7: 37-47.
51. Shemesh E, Czerniak A, Nass S, Klein E. Role of endoscopic retrograde cholangiopancreatography in differentiating pancreatic cancer coexisting with chronic pancreatitis. Cancer 1990; 65(4): 893-6.
52. Chang KJ, Albers CG, Erickson RA, Butler JA, Wuerker RB, Lin F. Endoscopic ultrasound-guided line needle aspiration of pancreatic carcinoma. Am J Gastroenterol 1994; 89(2): 263-6.
53. Ihse I, Toregard BM, Akerman M. Intraoperative line needle aspiration cytology in pancreatic lesions. Ann Surg 1979; 100: 732-4.
54. Al-Kaisi N, Siegler EE. Fine needle aspiration cytology of the pancreas. Acta Cytol 1989; 33: 145-52.
55. Parsons L, Palmer CH. How accurate is line needle biopsy in malignant neoplasia of the pancreas? Arch Surg 1989; 124: 681-3.
56. Jorda M, Essenfeld H, Garcia E, Ganjei P. The value of line needle aspiration cytology in the diagnosis of inflamatory pancreatic masses. Diagnostic Cytopathol 1992; 8(1): 65-7.
57. Carson HJ, Green LK, Castelli MJ, Reyes CV, Prinz RA, Gattuso P. Utilization of line needle aspiration biopsy in the diagnosis of metastatic tumours to the pancreas. Diagnostic Cytopathol 1995; 12(1): 8-13.
58. Delmaschio A, Vanzulli A, Sironi S, et al. Pancreatic cancer versus chronic pancreatitis: Diagnosis with CA 19-9 assessment, US, CT and CT-guided line needle biopsy. Radiology 1991; 178(1): 95-9.
59. Warshaw AL. Implications of peritoneal cytology for staging, of early pancreatic cancer. Am J Surg 1991; 161(1): 26-9.
60. McCarthy MJ, Evans J, Sagar G, Neoptolemos JP. Prediction of resectability for pancreatic malignancies by computed tomography. Br J Surg 1998; 85(3): 320-5.
61. Freeny PC, Traverso LW, Ryan JA. Diagnosis and staging of pancreatic adenocarcoma with dynamic computed tomography. Am J Surg 1993; 165: 600-6.
62. Bovo P, Rigo L, Togni M, et al. Rapid diagnosis of pancreatic cancer by combination of ultrasonography and serum tumour markers CA19-9 and CA50. Italian J Gastroenterol 1993; 25(9): 477-81.
63. Honda H, Kusumoto S, Nishikawa K, et al. Limitation of CT in diagnosis of pancreatic cancer. Radiation Med 1991; 9(2): 61-7.
64. Warshaw AL, Gu ZY, Wittenberg J, Waltman AC. Preoperative staging and assessment of resect ability of pancreatic cancer. Arch Surg 1990; 125(2): 230-5.
65. Fernandez-Del Castillo C, Rattner DW, Warshaw AL. Further experience with laparoscopy and peritoneal cytology in the staging of pancreatic cancer. Br J Surg 1995; 82: 1127-9.
66. Conlon KC, Dougherty E, Klimstra DS. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg 1996; 223: 134-40.
67. John TG, Greig JD, Carter DC, Garden OJ. Carcinoma of the pancreatic head and periampullary region. Tumour staging with laparoscopy and laparoscopic ultrasonography. Ann Surg 1995; 221: 156-64.
68. Declore R, Thomas JH, Hermreck A. Pancreaticoduodenectomy for malignant pancreatic neoplasms in elderly patients. Am J Surg 1991; 162: 532-5.
69. Spencer MP, Sarr MG, Nagorney DM. Radical pancreatectomy for pancreatic cancer in the elderly: is it safe and justified. Ann Surg 1989; 212: 140-3.
70. Neoptolemos JP, Kerr DJ, Beger H, et al. ESPAC-1 trial progress report: the European randomized adjuvant study comparing radiochemotherapy, six months chemotherapy and combination therapy versus observation in pancreatic cancer. Digestion 1997; 58(6): 570-7.
71. Nghiem HV, Freeny PC. Radiologic staging of pancreatic adenocarcinoma. Radiol Clin North Am 1994; 32: 71-9.
72. Pleskow DK, Berger HJ, Gyves J, Allen F, McLean A, Podolsky DK. Evaluation of a serologic marker CA 19-9 in the diagnosis of pancreatic cancer. Ann Intern Med 1989; 110: 704-9.
73. Steinberg W. The clinical utility of the CA 19-9 tumour associated antigen. Am J Gastroenterol 1990; 85: 350-5.
74. Gullo L, Pezzilli R, Ventrucci M, et al. Serum immunoreactive elastase - is it useful for the diagnosis of pancreatic cancer? Pancreas 1989; 4(3): 335-8.
75. Robles-Diaz G, Diaz-Sanchez V, Fernandez-del Castillo C, et al. Serum testosterone: dihydrotesterone ratio and CA 19-9 in the diagnosis of pancreatic cancer. Am J Gastroenterol 1991; 86(5): 591-4.
76. Allison DC, Bose KK, Hruban RH, et al. Pancreatic cancer cell DNA content correlates with long term survival after pancreatoduodenectomy. Ann Surg 1991; 214(6): 648-56.
77. Eskelinen M, Lipponen P, Collan Y, Marin S, Alhava K, Nordling S. Relationship between DNA ploidy and survival in patients with exocrine pancreatic cancer. Pancreas 1991; 6(1): 90-5.
78. Weger AR. Nuclear DNA distribution pattern of the parenchymal cells in adenocarcinomas of the pancreas and in chronic pancreatitis. Gastroenterology 1990; 99: 237-42.
79. Juhl H, Schmiegel W, Kalthoff H. Clinical applications of cancer-associated antigens. In: Neoptolemos JP, Lemoine NR, eds. Pancreatic Cancer: Molecular and Clinical Advances. Oxford: Blackwell, 1996: 214-23.
80. Mahvi DM, Meyers WC, Bast RC, Seigler HP, Melgzar RS. Therapeutic efficacy as defined by a sero-diagnostic test utilising a monoclonal antibody in carcinoma of the pancreas. Ann Surg 1985; 202(4): 440.
81. Lan MS, Finn OJ, Fernstein PD, Metzgar RS. Isolation and properties of a human pancreatic adenocarcinoma-associated antigen, DU-PAN-2. Cancer Res 1985; 45(1): 305-10.
82. Cold DV, Lew K, Maliniak R, Hernandez M, Cardillo T. Characterisation of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer 1994; 57(2): 204-10.
83. Gold D, Alisauskas R, Sharkey RM. Targetting of xenografted pancreatic cancer with a new monoclonal antibody PAM4. Cancer Res 1995; 55: 1105-10.
84. Kiriyama S, Hayakawa T, Kondo T, et al. Usefulness of a new tumour marker SPAN-1, for the diagnosis of pancreatic cancer. Cancer 1990; 65(7): 1557-61.
85. Yuan SZ, Ho JJL, Yuan M, Kim YS. Human pancreatic cancer associated antigens detected by murine monoclonal antibodies. Cancer Res 1985; 45(12): 6179-87.
86. Nilsson O, Munsson JE, Lindholm L, Holmgren J, Svennerholm L. Sialosys-lacto-tetraosyl-ceramide, a novel gangliocide antigen detected in human carcinomas by a monoclonal antibody. FEBS Lett 1985; 182(2): 398-402.
87. Rothlin MA, Joller H, Largiader F. CA242 is a new tumor marker for pancreatic cancer. Cancer 1993: 71(3): 701-7.
88. Friess H, Buchler M, Auerbach B, et al. CA494 - a new tumor marker for the diagnosis of pancreatic cancer. Int J Cancer 1993; 53(5): 759-63.
89. Ruhin D, Warshaw AL, Southern JF, Pins M, Compton CC, Lewandrowski KB. Expression of CA15-3 protein in the cyst contents distinguishes benign from malignant pancreatic mucinous cystic neoplasms. Surgery 1994; 115(1): 52-5.
90. Byrne DJ, Browning MCK, Cuschieri A. CA72-4: a new tumour marker for gastric cancer. Br J Surg 1990; 77(9): 1010-13.
91. Lewandrowski K, Lee J, Southern J, Centeno B, Warshaw A. Cyst fluid analysis in the differential diagnosis of pancreatic cysts. Ann Surg 1993: 217(1): 41-7.
92. Parker N, Makin CA, Ching CK, et al. A new enzyme-linked lectin/mucin antibody sandwich assay (CAM17.1/WGA) assessed in combination with CA19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer. Cancer 1992; 70: 1062-8.
93. Yiannakou JY, Newland P, Calder F, Kingsnorth AN, Rhodes JM. Prospective study of CAM17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet 1997; 349: 389-92.
94. Rhodes J, Ching C. Serum diagnostic tests for pancreatic cancer. Ballieres Clinic Gastroenterol 1990; 4: 833-52.
95. Satake K, Takeuchi T. Comparison of CA19-9 with other tumour markers in the diagnosis of cancer of the pancreas. Pancreas 1994; 9(6): 720-4.
96. Matsumoto S, Harada H, Tanaka J, et al. Evaluation of cytology and tumour markers of pure pancreatic juice for the diagnosis of pancreatic cancer at early stages. Pancreas 1994; 9(6): 741-7.
97. Banfi G, Zerbi A, Pastori S, Parolini D, Di Carlo V, Bonini P. Behaviour of tumour markers CA19-9, CA195, CAM43, CA242 and TPS in the diagnosis and follow up of pancreatic cancer. Clin Chem 1993; 39(3): 420-3.
98. Richter JM, Christensen MR, Rustgi AK, Silverstein MD. The clinical utility of the 19-9 radioimmunoassay for the diagnosis of pancreatic cancer presenting as pain or weight loss. An effectiveness analysis. Arch Intern Med 1989; 149(10): 2292-7.
99. Meduri F, Doni MG, Merenda R, et al. The role of the leukocyte adherence inhibition (LAI), CA 19-9 and tissue polypeptide antigen (TPA) tests in the diagnosis of pancreatic cancer. Cancer 1989; 64(5): 1103-6.
100. Haglaund C. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. Br J Cancer 1986; 54: 897-901.
101. Yasue M, Sakamoto J, Teramukai S, et al. Prognostic values of preoperative and postoperative CEA and CA19-9 levels in pancreatic cancer. Pancreas 1994; 9(6): 735-40.
102. Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and prediction of unresectability using the tumour associated antigen CA19-9. Pancreas 1994; 9(6): 731-4.
103. Kuno N, Kurimoto K, Fukushima M, et al. Effectiveness of multivariate analysis of tumour markers in diagnosis of pancreatic carcinoma: a prospective study in multi-institutions. Pancreas 1994; 9(6): 725-30.
104. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients. Anticancer Res 1992; 12: 2309-14.
105. Vilardell F, Farre-Viladrich A. Tumor markers in cancer of the pancreas. Front Gastrointest Res 1986; 12: 137-71.
106. Del Villano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody defined tumor marker CA19-9. Clin Chem 1985; 29(3): 549-52.
107. Warshaw AL, Swanson RS. Pancreatic cancer in 1988: possibilities and probabilities. Ann Surg 1988; 208: 541-53.
108. Neoptolemos JP, Lemoine NR. Pancreatic Cancer: Molecular and Clinical advances. Oxford: Blackwell Science Ltd, 1996.
109. Shibata D, Capella G, Perucho M. Mutational activation of the k-ras gene in pancreatic carcinoma. Ballieres Clin Gastroenterol 1990; 4: 151-69.
110. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-9.
111. Scarpa A, Capelli P, Villanueva A, et al. Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. Int J Cancer 1994; 57: 167-71.
112. Almoguera C, Shibata D, Forester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-54.
113. Gonzalez-Cadavid NF, Zhou D, Battifora H, Bareli M, Cline MJ. Direct sequencing analysis of exon 1 of the c-K-ras gene shows a low frequency of mutuations in human pancreatic adenocarcinomas. Oncogene 1989; 4(9): 1137-40.
114. Hruban RH, Vanmansfeld ADM, Offerhaus GJA, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143(2): 545-54.
115. Levi S, Urbano-Ispizua A, Gill R, et al. Multiple k-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991; 51(13): 3497-502.
116. Stork P, Loda M, Bosari S, Wiley B, Poppenhausen K, Wolfe H. Detection of k-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. Oncogene 1991; 6: 857-62.
117. Satoh K, Sawai T, Shimosegawa T, et al. The point mutation of c-Ki-ras at codon 12 in carcinoma of the pancreatic head region and in intraductal mucin hypersecreting neoplasm of the pancreas. Int J Pancreatol 1993; 14: 135-43.
118. Yashimo T, Fulton N, Hara H, et al. Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumours. Surgery 1993; 114: 758-64.
119. Kalthoff H, Schmiegel W, Roeder C, et al. P.53 and K ras alterations in pancreatic cell lesions. Oncogene 1993; 8(2): 289-98.
120. Lemoine NR, Jain S, Hughes CS, et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992; 102(1): 230-6.
121. Scarpa A, Zamboni G (eds). Genetic Abnormalities in Pancreatic Carcinoma. Oxford. Blackwell Science Ltd, 1995.
122. Tada M, Omata M, Kawai S, et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993; 53(11): 2472-4.
123. Kondo H, Sugano K, Fukayama N, et al. Detection of point mutations in the k-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 1994; 73(6): 1589-94.
124. Caldas C, Hahn SA, Hruban RH, Redston RH, Yeo CJ, Kern SE. Detection of k-ras mutations in the stool of patients with adenocarcinoma and pancreatic duct hyperplasia. Cancer Res 1994; 54(13): 3568-73.
125. Shibata D, Almoguera C, Forrester K, et al. Detection of c-K-ras mutations in line needle aspirates from human pancreatic adenocarcinomas. Cancer Res 1990; 50(4): 1279-83.
126. Berthelemy P, Bouisson M, Escourrou J, Vayasse N, Rumeau JL, Pradayrol L. Identification of k-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 1995; 123(3): 188-91.
127. Van Laethem JL, Bourgeois V, Delhaye M, et al. Ki-ras mutations in patients with chronic pancreatitis: high prevalence but undetermined relevance. Gastroenterology 1997; 112(4): A490.
128. Lemoine NR, Hughes CM, Barton CM, et al. The epidermal growth factor receptor in human pancreatic cancer. J Pathol 1992; 166(1): 7-12.
129. Yamanaka Y. The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erb-B2 oncoprotein in human pancreatic cancer. Nippon Ika Daigaku Zasshi (J Nippon Med School) 1992; 59: 51-61.
130. Friess H, Yamanaka Y, Buchler M, Kobrin MS, Tahara E, Korc M, Cripto, a member of the epidermal growth factor family is overexpressed in human pancreatic cancer and chronic pancreatitis. Int J Cancer 1994; 56(5): 668-74.
131. Friess H, Buchler MW, Korc M. Growth factors and growth factor receptors in pancreatic cancer. In: Neoptolemos JP, Lemoine NR, eds. Pancreatic Cancer: Molecular and Clinical Advances. Oxford: Blackwell, 1996:51-60.
132. Kaweshaw A, Evans JD, Kinsella A, et al. P53 overexpression does not correlate with prognosis in pancreatic cancer. Digestion 1997; 58(2): 1-61.
133. Barton CM, Staddon SL, Hughes CM, et al. Abnormalities of the P53 tumor suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64(6): 1076-82.
134. Lemoine NR. The molecular pathology of pancreatic cancer. In: Beger H, Buchler M, Malfertheiner P, eds. Standards in Pancreatic Surgery. Berlin: Springer-Verlag, 1995.
135. Ruggeri B, Zhang SY, Caamano J, Dirado M, Flynn SD, Kleinszanto AJP. Human pancreatic carcinoma and cell lines reveal frequent and multiple alterations in the P53 and RD-1 tumor suppressor genes. Oncogene 1992; 7(8): 1503-11.
136. Casey G, Yamanaka Y, Eriess H, et al. P53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993; 69(3): 151-60.
137. Nakamori S, Yashima K, Murakami Y, et al. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jap J Cancer Res 1995; 86: 174-81.
138. Hahn SA, Hoque A, Moskaluk CA, et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 1996; 56(3): 490-4.
139. Hahn SA, Schutte M, Hoque A, et al. Dpc4, a candidate tumor-suppressor gene at human-chromosome 18q21.1. Science 1996; 271(5247): 350-3.
140. Whelan AJ, Bartsch D, Goodfellow PJ. A familial syndrome of pancreatic-cancer and melanoma with a mutation in the Cdkn2 tumor-suppressor gene. New Engl J Med 1995; 333(15): 975-7.
141. Schutte M, Dacosta LT, Hahn SA, et al. Identification by representational difference analysis of a homozygous deletion in pancreatic-carcinoma that lies within the Brca2 region. Proc Natl Acad Sci USA 1995; 92(13): 5950-4.
142. Tavtigian SV, Simard J, Rommens J, et al. The complete Brca2 gene and mutations in chromosome 13q-linked kindreds. Nature Genet 1996; 12(3): 333-7.
143. Johansson U, Sellberg C, Brondumnielsen K, Sele V, Olsson H. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet 1996; 58: 441-50.
144. Lynch HT, Smyrk T, Kern SE, et al. Familial pancreatic-cancer - a review. Seminars Oncol 1996; 23(2): 251-75.
145. McKie AB, Filipe MI, Lemoine NR. Abnormalities affecting the APC and NCC tumour suppressor gene loci in chromosome 5q occur frequently in gastric cancer but not in pancreatic cancer. Int J Cancer 1993; 55(4): 598-603.
146. Leung HY, Lemoine NR. Pancreatic cancer. In: Lemoine N, Neoptolemos J, Cooke T, eds. Cancer: a Molecular Approach. Oxford: Blackwell Scientific, 1996:105-15.
147. Han HJ, Yanagisawa YK, Park JG, Nakamura Y. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res 1993; 53(21): 5087-9.
148. Seymour AB, Hruban RH, Redston M, et al. Allelotype of pancreatic carcinoma. Cancer Res 1994; 54(10): 2761-4.
149. Simon B, Weinel R, Hohne M, et al. Frequent alterations of the tumour-suppressor genes P53 and DCC in human pancreatic carcinoma. Gastroenterology 1994; 106(6): 1045-51.
150. Joensuu H, Alanen KA, Klemi PJ. Doubts on 'curative' resection of pancreatic cancer. Lancet 1989; 1(8644): 953-4.
151. Porschen R, Remy U, Bevers G, Schauseil S, Hengels KJ, Borchard F. Prognostic significance of DNA ploidy in adenocarcinoma of the pancreas: a flow cytometric study of paraffin embedded specimens. Cancer 1993; 71(12): 3846-50.
152. Nakamori S, Ishikawa O, Ohigashi H, et al. Expression of nucleoside diphosphate kinase nm23 gene product in human pancreatic cancer, an association with lymph node metastasis and tumour invasion. Clin Exp Metastasis 1993; 2: 151-8.